|
|
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date20 Jan 1800 |
A Dose Escalation Safety and Pharmacokinetic Study of SAR103168 Administered as a Single Agent by Intravenous Infusion, Once Daily for 5 Consecutive Days to Patients With Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes.
Primary objectives:
To determine the maximum tolerated dose (MTD) of SAR103168 and to characterize the dose limiting toxicities (DLTs) in the proposed dose regimen
To evaluate the pharmacokinetic (PK) profile of SAR103168
Secondary objectives:
To characterize the global safety profile of SAR103168
To evaluate preliminary anti-leukemia activity
To investigate the potential induction effect on CYP3A4 and persistence of this effect by using oral midazolam as a probe substrate in patients enrolled into the expanded cohort at the MTD
To determine the metabolic pathways of SAR103168 and identify the chemical structures of metabolites
To determine the potential impact of SAR103168 on the QTc interval in patients enrolled at the MTD
100 Clinical Results associated with ABL x FGFR3 x VEGFR1 x EGFR x PDGFR x VEGFR2 x FGFR1 x SRC x Tie-2
100 Translational Medicine associated with ABL x FGFR3 x VEGFR1 x EGFR x PDGFR x VEGFR2 x FGFR1 x SRC x Tie-2
0 Patents (Medical) associated with ABL x FGFR3 x VEGFR1 x EGFR x PDGFR x VEGFR2 x FGFR1 x SRC x Tie-2